Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/3076% below fair value
$0.42+0.03 (+8.06%)
Close on Nov 13, 2026Market cap $8.14MP/E –Yield –
Ensysce Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Ensysce Biosciences's operating margin for the twelve months ending Sep 30, 2026 was -1477.0%. For fiscal 2025 it was -202.1%, against -129.2% the year before. The highest annual figure on record is -41.0% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -202.1% | −72.9 |
| FY2024 | Dec 31, 2024 | -129.2% | +351.3 |
| FY2023 | Dec 31, 2023 | -480.5% | +479.4 |
| FY2022 | Dec 31, 2022 | -959.9% | −397.2 |
| FY2021 | Dec 31, 2021 | -562.7% | −521.7 |
| FY2020 | Dec 31, 2020 | -41.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3781.4% | −3022.7 |
| Q2 FY2026 | Jun 30, 2026 | -221.3% | −93.6 |
| Q1 FY2026 | Mar 31, 2026 | -370.7% | −221.6 |
| Q4 FY2025 | Dec 31, 2025 | -147.8% | +126.6 |
| Q3 FY2025 | Sep 30, 2025 | -758.7% | −777.5 |
| Q2 FY2025 | Jun 30, 2025 | -127.6% | +948.0 |
| Q1 FY2025 | Mar 31, 2025 | -149.1% | +453.7 |
| Q4 FY2024 | Dec 31, 2024 | -274.3% | +338.4 |
| Q3 FY2024 | Sep 30, 2024 | 18.9% | +640.7 |
| Q2 FY2024 | Jun 30, 2024 | -1075.6% | −607.9 |
| Q1 FY2024 | Mar 31, 2024 | -602.8% | −278.5 |
| Q4 FY2023 | Dec 31, 2023 | -612.7% | −180.1 |
| Q3 FY2023 | Sep 30, 2023 | -621.8% | +1584.5 |
| Q2 FY2023 | Jun 30, 2023 | -467.7% | +2932.9 |
| Q1 FY2023 | Mar 31, 2023 | -324.4% | +472.0 |
| Q4 FY2022 | Dec 31, 2022 | -432.6% | −309.9 |
| Q3 FY2022 | Sep 30, 2022 | -2206.3% | −800.0 |
| Q2 FY2022 | Jun 30, 2022 | -3400.6% | −3307.7 |
| Q1 FY2022 | Mar 31, 2022 | -796.4% | −587.1 |
| Q4 FY2021 | Dec 31, 2021 | -122.7% | +139.8 |
| Q3 FY2021 | Sep 30, 2021 | -1406.3% | −1357.4 |
| Q2 FY2021 | Jun 30, 2021 | -92.8% | −100.4 |
| Q1 FY2021 | Mar 31, 2021 | -209.2% | – |
| Q4 FY2020 | Dec 31, 2020 | -262.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -48.9% | – |
| Q2 FY2020 | Jun 30, 2020 | 7.6% | – |
See a number that looks wrong?